Hyperuricemia
Conditions
Interventions
1:Non-drug therapy (dietary therapy, behavioral intervention) + Qihuatongtiao Formula granule (Astragalus membranaceus 6g, Bupleurum chinense 3g, Atractylodes macrocephala 9.23g, Polyporus umbellatus
2: Non-drug therapy (dietary therapy behavioral intervention) + Optimized Qihuatongtiao Formula granule (Astragalus membranaceus 9g Citrus aurantium 6.75g Poria cocos 1.8g Angelica sinensis 15g) 1 dos
3:Non-drug therapy (dietary therapy behavioral intervention) course of treatment: 8 weeks
Sponsors
Institute of Basic Theory of Chinese Medicine China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Here is the translation of the provided criteria into English: 1. Age between 18 and 65 years, with no gender restrictions; 2. Meet the aforementioned diagnostic criteria for the asymptomatic phase of HUA; 3. Meet the aforementioned traditional Chinese medicine diagnostic criteria for dampness and turbidity syndrome in HUA; 4. Have not taken antibiotics or immunosuppressants in the past 3 months, and have not participated in any clinical studies; 5. Voluntarily participate in this trial, understand the content and requirements of the trial, and have signed the informed consent form; 6. Have not yet received HUA treatment, or have received other HUA treatments but have undergone a washout period of more than 2 weeks; 7. Serum uric acid (SUA) levels reach the starting point for drug intervention and are less than 600 µmol/L.
Exclusion criteria
Exclusion criteria: Here is the translation of the provided exclusion criteria into English: 1. Those with comorbid kidney diseases (such as chronic urate nephropathy, uric acid nephrolithiasis, chronic kidney disease, acute kidney injury, etc., and eGFR = 60 mL/(min·1.73m²)), cardiovascular diseases (such as hypertension, coronary heart disease, heart failure, etc.), neurological diseases (stroke, neurodegenerative diseases, etc.), liver diseases (including abnormal liver function, with ALT, AST exceeding the upper limit of the normal range by more than 1.5 times), lung diseases, hematopoietic system diseases, and malignant tumors, severe infections, and other serious diseases; 2. Those who have entered the symptomatic phase of gout; 3. Those with incomplete required test indicators; 4. Those who have participated in other clinical trials within the last month and may affect this trial; 5. Those who are allergic to the components of the trial medication; 6. Those who are pregnant or breastfeeding, or women who plan to become pregnant in the near future; 7. Those who have taken medications that increase or decrease blood uric acid levels within the last month, or have received other treatments that may affect the efficacy indicators of this study (such as cardiovascular disease patients who are using or must use diuretics, aspirin, etc., affecting SUA medications, or those who have taken other types of urate-lowering drugs and dampness-dispelling and turbidity-reducing traditional Chinese medicines like allopurinol, benzbromarone within the last month); 8. Those who are unable to cooperate, such as patients with mental illnesses; 9. Those who are alcoholics or drug users; 10. Other situations deemed unsuitable by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum uric acid;Intestinal flora;TCM Syndrome Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrocardiogram (ECG);Blood Lipids (HDL-C LDL-C etc.);SF-36 Health Questionnaire;Urine Routine;Liver and Kidney Function (ALT Scr);Blood Routine;Blood Pressure Measurement;Physical Examination (Weight WC etc.);Body Fluid Distribution Measurement; | — |
Countries
China
Contacts
Public ContactYang Jinsheng
China Academy of Chinese Medical Sciences
Outcome results
None listed